Milestone decision authority

The transfer to milk of risperidone and its active metabolite 9-hydroxyrisperidone has been examined in two breast-feeding women and in one woman with risperidone-induced galactorrhea (209). The milkrplasma concentration ratio was under 0.5 for both compounds the calculated relative infant doses were 2.3%, 2.8%, and 4.7% of that of women s weight-adjusted doses neither compound was detected in the plasma of the two babies, who achieved their developmental milestones satisfactorily and did not have any adverse effect attributable to risperidone. The authors concluded that maternal risperidone therapy is unlikely to pose a significant hazard to the breast-fed infant in the short term, and recommended an individual benefit-harm analysis to take decisions about this issue. 

---